Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight

[1] Mok TS(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-957

[2] Wu YL(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-2388

[3] Thongprasert S(2003)Severe acute interstitial pneumonia and gefitinib Lancet 361 137-139

[4] Yang CH(2007)Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer BMC cancer 7 150-1044

[5] Chu DT(2007)Pulmonary toxicity associated with Erlotinib* Chest 132 1042-2556

[6] Saijo N(2006)Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 24 2549-424

[7] Sunpaweravong P(2005)Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group Cancer J 11 417-184

[8] Han B(2010)Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group Experience J Thorac Oncol 5 179-104

[9] Margono B(2004)Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib Lung Cancer 45 93-105

[10] Ichinose Y(2010)Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma Chang Gung Med J 33 100-170

[1] Mok TS(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-957

[2] Wu YL(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-2388

[3] Thongprasert S(2003)Severe acute interstitial pneumonia and gefitinib Lancet 361 137-139

[4] Yang CH(2007)Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer BMC cancer 7 150-1044

[5] Chu DT(2007)Pulmonary toxicity associated with Erlotinib* Chest 132 1042-2556

[6] Saijo N(2006)Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 24 2549-424

[7] Sunpaweravong P(2005)Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group Cancer J 11 417-184

[8] Han B(2010)Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group Experience J Thorac Oncol 5 179-104

[9] Margono B(2004)Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib Lung Cancer 45 93-105

[10] Ichinose Y(2010)Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma Chang Gung Med J 33 100-170